Actively Recruiting
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Led by Henry Ford Health System · Updated on 2026-02-24
43
Participants Needed
1
Research Sites
450 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
CONDITIONS
Official Title
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Diagnosed with AML, MDS, MPN, or CMML and underwent allogeneic stem cell transplant
- Experienced any drop in total or myeloid donor chimerism after day 30, or have myeloid donor chimerism below 98% without relapse
- Between 30 and 180 days post stem cell transplant
- Absolute neutrophil count greater than 1000
- Platelet count greater than 50,000
- Karnofsky performance score of at least 70%
- Adequate kidney function with creatinine clearance above 60 ml/min
- Adequate liver function with total bilirubin below 1.5 and ALT, AST, alkaline phosphatase less than 2.5 times normal
- Negative pregnancy test for women of childbearing potential who must use effective contraception
- Able to provide informed consent or have a legal representative do so
- Off prior chemotherapy, radiotherapy, or investigational therapy for at least 2 weeks before treatment start
You will not qualify if you...
- Positive for HIV, hepatitis B surface antigen, hepatitis C virus, or other viral hepatitis or cirrhosis
- Active or previous central nervous system leukemia unless in remission for at least 2 months
- History of serious chronic mental disorder or drug abuse causing poor treatment compliance
- Uncontrolled infection
- Grade III or IV graft versus host disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Henry ford hospital
Detroit, Michigan, United States, 48202
Actively Recruiting
Research Team
S
shatha farhan, MD
CONTACT
N
NALINI JANAKIRAMAN, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here